Edwards Lifesciences price target lowered by $7 at Barclays, here’s why

Barclays lowered the firm’s price target on Edwards Lifesciences to $90 from $97 and keeps an Overweight rating on the shares. The company’s tempered outlook for 2024 should reduce uncertainty and risk to quarterly execution, clearing the way for improving stock performance, the analyst tells investors in a research note. The firm also views the company’s expansion into interventional heart failure and the spin-off the slower growing Critical Care business as incremental positives for the stock.